Lazard Asset Management
YMAB

Lazard Asset Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Lazard Asset Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,812
Closed -$21K – 2560
2025
Q1 		$21K Buy
+4,812
New +$27.9K ﹤0.01% 2111
2024
Q4 		– Sell
-4,218
Closed -$55K – 2569
2024
Q3 		$55K Buy
+4,218
New +$53.5K ﹤0.01% 1905
2023
Q4 		– Sell
-12,384
Closed -$67K – 2503
2023
Q3 		$67K Buy
+12,384
New +$72.1K ﹤0.01% 1774
2022
Q3 		– Sell
-5,655
Closed -$85K – 2585
2022
Q2 		$85K Buy
+5,655
New +$66K ﹤0.01% 1576
2021
Q4 		– Sell
-1,801
Closed -$51K – 2484
2021
Q3 		$51K Buy
+1,801
New +$56.8K ﹤0.01% 1681
2021
Q2 		– Sell
-1,524
Closed -$46K – 2095
2021
Q1 		$46K Buy
+1,524
New +$62.5K ﹤0.01% 1474

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Lazard Asset Management's YMAB Position: Q2 2025 in Review

Lazard Asset Management sold out of Y-mAbs Therapeutics (YMAB) in Q2 2025, closing a stake of 4,812 shares — an estimated $21K sold.

Lazard Asset Management first reported a position in YMAB in Q1 2021 and held it in 6 quarters. The position peaked at $85K in Q2 2022. 97 funds tracked by Wall St. Rank hold YMAB as of Q2 2025.

  • Lazard Asset Management reported no remaining Y-mAbs Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Lazard Asset Management sold 4,812 Y-mAbs Therapeutics shares in Q2 2025, an estimated $21K.
  • Lazard Asset Management first reported a position in Y-mAbs Therapeutics in Q1 2021 and held it in 6 quarters.
  • Lazard Asset Management's Y-mAbs Therapeutics position peaked at $85K in Q2 2022.
  • 97 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q2 2025.

Based on Lazard Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.